Degenerative disease

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022 - 2:00am

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

The LGMD Community Celebrates Adoption of ICD-10 Diagnostic Codes for LGMD

Retrieved on: 
Wednesday, June 29, 2022 - 10:52pm

The implementation of these ICD-10 codes represents a culmination of two-years of collaborative efforts within the LGMD patient, clinical, and research communities.

Key Points: 
  • The implementation of these ICD-10 codes represents a culmination of two-years of collaborative efforts within the LGMD patient, clinical, and research communities.
  • These diagnostic codes will be fully implemented and ready for use starting this October.
  • This significant advance could well shorten the diagnostic odyssey for individuals with LGMD, facilitate the targeted care the community needs, and accelerate surveillance and epidemiological research.
  • This milestone is the culmination of over two years of collaborative efforts between LGMD advocacy organizations and leading LGMD clinicians and researchers.

C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research

Retrieved on: 
Wednesday, June 29, 2022 - 5:02pm

Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility.

Key Points: 
  • Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility.
  • Together with real data, these synthetic data will help maximize the utility of C-Path's Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), which provides a centralized and standardized infrastructure to support and accelerate rare disease characterization targeted to accelerate drug development.
  • It includes a robust, integrated database and analytics hub that allows for the aggregation of rare disease data from various sources and the efficient and effective interrogation of that data.
  • "Our collaboration with Replica Analytics is important because synthetic data can add value to real-world data while observing data privacy considerations, which will help accelerate overall rare disease drug development," said RDCA-DAP Scientific Director Alexandre Betourne, Pharm.D., Ph.D. "The goal of RDCA-DAP is to provide a centralized and standardized infrastructure to support and accelerate rare disease characterization and therapy development, this collaboration is in line with our efforts."

C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research

Retrieved on: 
Wednesday, June 29, 2022 - 4:09pm

Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility.

Key Points: 
  • Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility.
  • Together with real data, these synthetic data will help maximize the utility of C-Path's Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), which provides a centralized and standardized infrastructure to support and accelerate rare disease characterization targeted to accelerate drug development.
  • It includes a robust, integrated database and analytics hub that allows for the aggregation of rare disease data from various sources and the efficient and effective interrogation of that data.
  • "Our collaboration with Replica Analytics is important because synthetic data can add value to real-world data while observing data privacy considerations, which will help accelerate overall rare disease drug development," said RDCA-DAP Scientific Director Alexandre Betourne, Pharm.D., Ph.D. "The goal of RDCA-DAP is to provide a centralized and standardized infrastructure to support and accelerate rare disease characterization and therapy development, this collaboration is in line with our efforts."

Blackford Announces Partnership with Us2.ai For Advanced Echo Interpretation

Retrieved on: 
Wednesday, June 29, 2022 - 3:20pm

EDINBURGH, Scotland, June 29, 2022 /PRNewswire-PRWeb/ -- Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform. The Blackford Platform enables the seamless selection and integration of AI applications into medical imaging workflows, which supports the complex measurement and reporting needs of clinicians.

Key Points: 
  • Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform.
  • New AI tools on the platform can produce a fully automated echo report in under 2 minutes.
  • EDINBURGH, Scotland, June 29, 2022 /PRNewswire-PRWeb/ -- Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform.
  • The Blackford Platform enables the seamless selection and integration of AI applications into medical imaging workflows, which supports the complex measurement and reporting needs of clinicians.

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Retrieved on: 
Wednesday, June 29, 2022 - 3:07pm

The Company's lead product candidate, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine.

Key Points: 
  • The Company's lead product candidate, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine.
  • CardiolRx is currently being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the "LANCER" trial).
  • For more information about Cardiol Therapeutics, please visit cardiolrx.com .
  • These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information.

JHLT: Tops in Transplantation

Retrieved on: 
Wednesday, June 29, 2022 - 2:00pm

Journal of Heart and Lung Transplantation increases Impact Factor, maintains #1 ranking among transplantation journals

Key Points: 
  • Journal of Heart and Lung Transplantation increases Impact Factor, maintains #1 ranking among transplantation journals
    JHLT'soverall 2021 Impact Factor is 13.569, up from 10.247 in 2020.
  • ISHLT is the only international interdisciplinary organization focused on interventions for advanced heart and lung disease, including transplantation.
  • The official publication of the International Society for Heart and Lung Transplantation, the Journal of Heart and Lung Transplantation brings readers essential scholarly and timely information in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy.
  • The International Society for Heart and Lung Transplantation is a not-for-profit, multidisciplinary professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies.

AGC Biologics Named Manufacturing Company of the year by American Business Awards

Retrieved on: 
Wednesday, June 29, 2022 - 2:09pm

AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents.

Key Points: 
  • AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents.
  • Through these investments, AGC Biologics is establishing a reputation as one of the fastest-growing and innovative companies within the life science field.
  • The Longmont campus is the newest manufacturing site in the companys global network and serves as AGC Biologics North American hub for cell and gene therapy manufacturing.
  • Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service.

Bayer Opens New Research & Innovation Center in Boston-Cambridge Demonstrating Its Commitment to Precision Oncology

Retrieved on: 
Wednesday, June 29, 2022 - 1:07pm

In addition, the center comprises a newly established research team focused on leveraging chemical biology techniques to further propel the companys oncology drug development process.

Key Points: 
  • In addition, the center comprises a newly established research team focused on leveraging chemical biology techniques to further propel the companys oncology drug development process.
  • View the full release here: https://www.businesswire.com/news/home/20220628006207/en/
    Bayers new Research Center is located in the top two floors.
  • Bayer is undergoing significant growth in the United States in both research and development and our commercial operations, said Sebastian Guth, Ph.D., President of Bayer Pharmaceuticals, Americas Region.
  • The opening of our new precision molecular oncology research center in Kendall Square reflects the deep commitment Bayer is making to scale our oncology presence in the United States.

New Campaign Says Federal Response to HIV in Canada is "Stuck in the Past" Ahead of International AIDS Conference

Retrieved on: 
Wednesday, June 29, 2022 - 1:45pm

The campaign encourages people across Canada to sign letters to the Minister of Health, which call for an increase in HIV funding in Canada to $100 million annually, and better engagement with organizations and people living with HIV.

Key Points: 
  • The campaign encourages people across Canada to sign letters to the Minister of Health, which call for an increase in HIV funding in Canada to $100 million annually, and better engagement with organizations and people living with HIV.
  • As a member of the National Advocates, CBRC is one of 18 organizations that came together to develop the campaign.
  • "Amidst a rising demand for services, a lack of federal funding has forced many community-based HIV organizations to end services or shut down."
  • "We have a responsibility to address HIV in Canada, not just to protect the health of Canadians, but to avoid further inequities.